mvjrМедицинский вестник Юга РоссииMedical Herald of the South of Russia2219-80752618-7876The Rostov State Medical University10.21886/2219-8075-2020-11-3-6-14mvjr-1084Research ArticleОБЗОРЫREVIEWОтмена препаратов в психиатрии: проблемы и возможностиDeprescribing in psychiatry: challenges and opportunitieshttps://orcid.org/0000-0002-2743-3223БибековаЖ. Б.BibekovaZh. B.

Жазира Бектурсыновна Бибекова — ассистент кафедры неврологии, нейрохирургии, психиатрии и реабилитологии

Караганда

Zhazira B. Bibekova — assistant of Neurology, neurosurgery, psychiatry and rehabilitology department

Karaganda

zhaz88@bk.ruhttps://orcid.org/0000-0003-2787-4536ЗаровныйК. В.ZarovnyyKirill Vladimirovich

Кирилл Владимирович Заровный — врач-резидент кафедры неврологии, нейрохирургии, психиатрии и реабилитологии

Караганда

Kirill V. Zarovnyy — resident doctor of Neurology, neurosurgery, psychiatry and rehabilitology department

Karaganda

kirill_777_09@list.ruhttps://orcid.org/0000-0002-0695-5479ЦыгановаВ. О.TsyganovaV. O.

Виктория Олеговна Цыганова — врач-резидент кафедры психиатрии, наркологии и неврологии

Алмата

Viktoriya O. Tsyganova — resident doctor of psychiatry, narcology and neurology department

Almaty

viki_13@inbox.ruМедицинский Университет КарагандыКазахстанKaraganda Medical UniversityKazakhstanМедицинский университет КарагандыКазахстанKaraganda Medical UniversityKazakhstanКазахстанско-Российский медицинский университетКазахстанKazakh-Russian Medical UniversityKazakhstan202025092020113614Copyright © Бибекова Ж.Б., Заровный К.В., Цыганова В.О., 20202020Бибекова Ж.Б., Заровный К.В., Цыганова В.О.Bibekova Z.B., Zarovnyy K.V., Tsyganova V.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medicalherald.ru/jour/article/view/1084

Многие рекомендации, протоколы описывают показания к началу приема лекарств, но только некоторые из них указывают, когда их приём следует прекратить. Анализ публикаций указывает на дефицит исследований в этой области, особенно в психиатрии. В рамках этого обзора мы постарались предоставить информацию, которая предоставляет ценную информацию об этой процедуре, об опыте других стран. На основании обзора литературы было установлено, что в некоторых странах уже существует консенсус в отношении того, как определить пациента, лечение которого может быть отменено, для этой процедуры были разработаны рекомендации и алгоритмы с минимальным риском для пациента.

Many recommendations, protocols describe the indications for starting medication, but only some of them indicate when they should be discontinued. An analysis of publications indicates a deficit of research in this area, especially in psychiatry. As part of this review, we tried to provide information that provides valuable information about this procedure, about the experience of other countries. Based on a literature review, it was found that in some countries there is already consensus on how to identify a patient who may be reevaluated, recommendations and algorithms have been developed for this procedure with minimal risk to the patient.

депрескрайбинглечениеотмена леченияпсихиатрияполипрагмазияобзорdeprescribingtreatmentwithdrawal of treatmentpsychiatrypolypharmacyreviewReferencesAilabouni N.J., Nishtala P.S., Mangin D., Tordoff J.M. Challenges and Enablers of Deprescribing: A General Practitioner Perspective. // PLoS One. – 2016. – V.11(4). - e0151066. https://doi.org/10.1371/journal.pone.0151066Ailabouni NJ, Nishtala PS, Mangin D, Tordoff JM. Challenges and Enablers of Deprescribing: A General Practitioner Perspective. PLoS One. 2016;11(4). https://doi.org/10.1371/journal.pone.0151066Reeve E., Shakib S., Hendrix I., Roberts M.S., Wiese M.D. The benefits and harms of deprescribing. // Med J Aust. – 2014. – V.201. – P.386–9. https://doi.org/10.5694/mja13.00200Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. The benefits and harms of deprescribing. Med J Aust 2014; 201:386–9. https://doi.org/10.5694/mja13.00200Farrell B., Pottie K., Rojas-Fernandez C.H., Bjerre L.M., Thompson W., Welch V. Methodology for Developing Deprescribing Guidelines: Using Evidence and GRADE to Guide Recommendations for Deprescribing. // PLoS One. – 2016. – V.11(8). - e0161248. https://doi.org/10.1371/journal.pone.0161248Farrell B, Pottie K, Rojas-Fernandez CH, Bjerre LM, Thompson W, Welch V. Methodology for Developing Deprescribing Guidelines: Using Evidence and GRADE to Guide Recommendations for Deprescribing. PLoS One. 2016;11(8). https://doi.org/10.1371/journal.pone.0161248Scott I.A., Le Couteur D.G. Physicians need to take the lead in deprescribing. // Intern Med J. - 2015. – V.45(3). – P.352–6. https://doi.org/10.1111/imj.12693Scott IA, Le Couteur DG. Physicians need to take the lead in deprescribing. Intern Med J. 2015. March;45(3):352–6. https://doi.org/10.1111/imj.12693Betteridge T.M., Frampton C.M., Jardine D.L. Polypharmacy— we make it worse! A cross-sectional study from an acute admissions unit. // Intern Med J. – 2012. – V.42(2). – P.208– 11. https://doi.org/10.1111/j.1445-5994.2011.02690.xBetteridge TM, Frampton CM, Jardine DL. Polypharmacy—we make it worse! A cross-sectional study from an acute admissions unit. Intern Med J 2012. February;42(2):208–11. https://doi.org/10.1111/j.1445-5994.2011.02690.xFarrell B., Tsang C., Raman-Wilms L., Irving H., Conklin J., Pottie K. What are priorities for deprescribing for elderly patients? Capturing the voice of practitioners: a modified delphi process. // PLoS One. – 2015. – V.10(4). - e0122246. https://doi.org/10.1371/journal.pone.0122246Farrell B, Tsang C, Raman-Wilms L, Irving H, Conklin J, Pottie K. What are priorities for deprescribing for elderly patients? Capturing the voice of practitioners: a modified delphi process. PLoS One. 2015;10(4). https://doi.org/10.1371/journal.pone.0122246Reeve E., Wiese M.D. Benefits of deprescribing on patients’ adherence to medications. // International journal of clinical pharmacy. – 2014. – V.36(1). – P.26–9. https://doi.org/10.1007/s11096-013-9871-zReeve E, Wiese MD. Benefits of deprescribing on patients’ adherence to medications. International journal of clinical pharmacy 2014;36(1):26–9. https://doi.org/10.1007/s11096-013-9871-zGrudnikoff E., Bellonci C. Deprescribing in Child and Adolescent Psychiatry—A Sorely Needed Intervention. // American Journal of Therapeutics. - 2017. – V.24(1). e1-e2. https://doi.org/10.1097/MJT.0000000000000552.Grudnikoff, Eugene MD; Bellonci, Christopher MD. Deprescribing in Child and Adolescent Psychiatry—A Sorely Needed Intervention. American Journal of Therapeutics. 2017. 24(1):e1-e2. https://doi.org/10.1097/MJT.0000000000000552.Gupta S., Cahill J., Miller R. Deprescribing antipsychotics: A guide for clinicians. // BJPsych Advances. – 2018. – V.24(5). – P. 295-302. https://doi.org/10.1192/bja.2018.2Gupta, S., Cahill, J., & Miller, R. (2018). Deprescribing antipsychotics: A guide for clinicians. BJPsych Advances, 24(5), 295-302. https://doi.org/10.1192/bja.2018.2Woodward M.C. Deprescribing: Achieving Better Health Outcomes for Older People through Reducing Medications. // J. Pharm. Pract. Res. – 2003. – V.33. – P.323–328. https://doi.org/10.1002/jppr2003334323.Woodward M.C. Deprescribing: Achieving Better Health Outcomes for Older People through Reducing Medications. J. Pharm. Pract. Res. 2003;33:323–328. https://doi.org/10.1002/jppr2003334323.Sinnott C., Hugh S.M., Boyce M.B., Bradley C.P. What to give the patient who has everything? A qualitative study of prescribing for multimorbidity in primary care. // Br J Gen Pract. - 2015. – V.65(632). - e184–91. https://doi.org/10.3399/bjgp15X684001Sinnott C, Hugh SM, Boyce MB, Bradley CP. What to give the patient who has everything? A qualitative study of prescribing for multimorbidity in primary care. Br J Gen Pract 2015. March;65(632):e184–91. https://doi.org/10.3399/bjgp15X684001Schuling J., Gebben H., Veehof L.J., Haaijer-Ruskamp F.M. Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study. // BMC Fam Pract. – 2012. – V.13. – P.56. https://doi.org/10.1186/1471-2296-13-56Schuling J, Gebben H, Veehof LJ, Haaijer-Ruskamp FM. Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study. BMC Fam Pract 2012;13:56 https://doi.org/10.1186/1471-2296-13-56Schoen C., Osborn R., Squires D., Doty M., Pierson R., Applebaum S. New 2011 survey of patients with complex care needs in eleven countries finds that care is often poorly coordinated. // Health Aff (Millwood). – 2011. – V.30(12). – P.2437–48. https://doi.org/10.1377/hlthaff.2011.0923Schoen C, Osborn R, Squires D, Doty M, Pierson R, Applebaum S. New 2011 survey of patients with complex care needs in eleven countries finds that care is often poorly coordinated. Health Aff (Millwood) 2011;30(12):2437–48. https://doi.org/10.1377/hlthaff.2011.0923Gupta S., Cahill J. A Prescription for “Deprescribing” in Psychiatry. // Psychiatric services (Washington, D.C.). - 2016. – V.67(8). – P.904-907. https://doi.org/10.1176/appi.ps.201500359.Gupta, Swapnil & Cahill, John. A Prescription for "Deprescribing" in Psychiatry. Psychiatric services (Washington, D.C.). 2016. 67(8). https://doi.org/10.1176/appi.ps.201500359.Essock S.M., Covell N.H., Leckman-Westin E., Lieberman J.A., Sederer L.I., et al: Identifying clinically questionable psychotropic prescribing practices for Medicaid recipients in New York State. // Psychiatric Services. – 2009. – V.60(12). – P.1595–1602. https://doi.org/10.1176/ps.2009.60.12.1595Essock SM, Covell NH, Leckman-Westin E, et al: Identifying clinically questionable psychotropic prescribing practices for Medicaid recipients in New York State. Psychiatric Services/ 2009; 60(12): 1595–1602 https://doi.org/10.1176/ps.2009.60.12.1595Ganguly R., Kotzan J.A., Miller L.S., Kennedy K., Martin B.C. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. // Journal of Clinical Psychiatry. – 2004. – V.65(10). – P.1377–1388 https://doi.org/10.4088/jcp.v65n1013Ganguly R, Kotzan JA, Miller LS, et al: Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. Journal of Clinical Psychiatry. 2004;65(10):1377–1388 https://doi.org/10.4088/jcp.v65n1013Stahl S.M., Grady M.M. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. // Current Medicinal Chemistry. – 2004. – V.11(3). – P.313–327. https://doi.org/10.2174/0929867043456070Stahl SM, Grady MM: A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Current Medicinal Chemistry. 2004;11(3):313–327. https://doi.org/10.2174/0929867043456070Gupta S., Miller R. Deprescribing and Its Application to Psychiatry. In: Steingard S. (eds) Critical Psychiatry. Springer, Cham; 2019. https://doi.org/10.1007/978-3-030-02732-2_6Gupta, Swapnil & Miller, Rebecca. Deprescribing and Its Application to Psychiatry: Controversies and Clinical Implications. January 2019. 137-153. https://doi.org/10.1007/978-3-030-02732-2_6.Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. // Br J Clin Pharmacol. – 2014. – V.78(4). – P.738–47. https://doi.org/10.1111/bcp.12386Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. Br J Clin Pharmacol. 2014;78(4):738–47. https://doi.org/10.1111/bcp.12386Swofford CD, Kasckow JW, Scheller-Gilkey G, Inderbitzin LB. Substance use: a powerful predictor of relapse in schizophrenia. // Schizophr Res. – 1996. – V.20(1-2). – P.145- 151. https://doi.org/10.1016/0920-9964(95)00068-2Swofford, CD, Kasckow, JW, Scheller-Gilkey, G, et al. Substance use: a powerful predictor of relapse in schizophrenia. Schizophrenia Research. 1996;20(1-2): 145–51 https://doi.org/10.1016/0920-9964(95)00068-2Deegan PE, Drake RE. Shared decision making and medication management in the recovery process. // Psychiatr Serv. – 2006. – V. 57(11). – P. 1636-9. https://doi.org/10.1176/ps.2006.57.11.1636Deegan, PE, Drake, RE Shared decision making and medication management in the recovery process. Psychiatric Services, 2006;57(11): 1636–9. https://doi.org/10.1176/ps.2006.57.11.1636Stanhope V, Ingoglia C, Schmelter B, Marcus SC. Impact of person-centered planning and collaborative documentation on treatment adherence. // Psychiatr Serv. – 2013. – V. 64(1). – P. 76-9. https://doi.org/10.1176/appi.ps.201100489.Stanhope, V, Ingoglia, C, Schmelter, B, et al. Impact of person-centered planning and collaborative documentation on treatment adherence. Psychiatric Services, 2013; 64(1): 76–9. https://doi.org/10.1176/appi.ps.201100489.Jacobson L, Greeley D. What is recovery? A conceptual model and explication. // Psychiatric Services. – 2001. – V. 52(4). – P. 482–5. https://doi.org/10.1176/appi.ps.52.4.482Jacobson, L, Greeley, D. What is recovery? A conceptual model and explication. Psychiatric Services. 2001;52(4): 482–5. https://doi.org/10.1176/appi.ps.52.4.482Taylor DJ, Pruiksma KE. Cognitive and behavioural therapy for insomnia (CBT-I) in psychiatric populations: a systematic review. // Int Rev Psychiatry. – 2014. – V.26(2). – P.205-13. https://doi.org/10.3109/09540261.2014.902808Taylor DJ, Pruiksma KE. Cognitive and behavioural therapy for insomnia (CBT-I) in psychiatric populations: a systematic review. Int Rev Psychiatry. 2014;26(2):205–13. https://doi.org/10.3109/09540261.2014.902808Vincent G.K., Velkoff V. The next four decades: The older population in the United States: 2010-2050. // Current Population Reports. – 2010. – P.1-14.Velkoff V. The next four decades: The older population in the United States: 2010-2050. Current Population Reports 2010:1-14. http://books.google.com/books?id=gALA2NWAFZ4C.Alzheimer’s Association. 2015 Alzheimer’s disease facts and figures. // Alzheimers Dement. – 2015. – V. 11(3). – P. 332-84. https://doi.org/10.1016/j.jalz.2015.02.003Alzheimer’s Association. 2015 Alzheimer’s disease facts and figures. Alzheimers Dement. 2015; 11(3):332-84. https://doi.org/10.1016/j.jalz.2015.02.003Renn BN, Asghar-Ali AA, Thielke S, Catic A, Martini SR, et al. A Systematic Review of Practice Guidelines and Recommendations for Discontinuation of Cholinesterase Inhibitors in Dementia. // Am J Geriatr Psychiatry. – 2018. – V.26(2). – P.134-147. https://doi.org/10.1016/j.jagp.2017.09.027Renn BN, Asghar-Ali AA, Thielke S, et al. A Systematic Review of Practice Guidelines and Recommendations for Discontinuation of Cholinesterase Inhibitors in Dementia. Am J Geriatr Psychiatry. 2018;26(2):134–147. https://doi.org/10.1016/j.jagp.2017.09.027Birks JS, Grimley Evans J. Rivastigmine for Alzheimer’s disease. // Cochrane Database Syst Rev. – 2015. – V.4. - CD001191. https://doi.org/10.1002/14651858.CD001191.pub4.Birks JS, Chong LY, Grimley Evans J. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2015 (9). https://doi.org/10.1002/14651858.CD001191.pub4.Mitchell SL, Morris JN, Park PS, Fries BE. Terminal care for persons with advanced dementia in the nursing home and home care settings. // J Palliat Med. – 2004. – V.7(6). – P.808- 16. https://doi.org/10.1089/jpm.2004.7.808Mitchell SL, Morris JN, Park PS, Fries BE. Terminal care for persons with advanced dementia in the nursing home and home care settings. J Palliat Med. 2004 Dec; 7(6):808-16. https://doi.org/10.1089/jpm.2004.7.808Parsons C, Hughes CM, Passmore AP, Lapane KL. Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the disadvantaged dying? // Drugs Aging. – 2010. – V. 27(6). – P. 435-49. https://doi.org/10.2165/11536760-000000000-00000Parsons C, Hughes CM, Passmore AP, Lapane KL. Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the disadvantaged dying? Drugs Aging. 2010 Jun 1; 27(6):435-49. https://doi.org/10.2165/11536760-000000000-00000Vetrano DL, Tosato M, Colloca G, Topinkova E, Fialova D, et al. Polypharmacy in nursing home residents with severe cognitive impairment: results from the SHELTER Study. // Alzheimers Dement. – 2013. – V.9(5). – P.587-93.. https://doi.org/10.1016/j.jalz.2012.09.009.Vetrano DL, Tosato M, et al. Polypharmacy in nursing home residents with severe cognitive impairment: results from the SHELTER Study. Alzheimers Dement. 2013 Sep; 9(5):587-93. https://doi.org/10.1016/j.jalz.2012.09.009.Birks J. Cholinesterase inhibitors for Alzheimer’s disease. // Cochrane Database Syst Rev. – 2006. – V.1. - CD005593. https://doi.org/10.1002/14651858.CD005593Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25; (1):CD005593. https://doi.org/10.1002/14651858.CD005593Lin SK. Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion?. // Int J Neuropsychopharmacol. – 2020. – V.23(2). – P. 125–131. https://doi.org/10.1093/ijnp/pyz068Lin SK. Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion?. Int J Neuropsychopharmacol. 2020;23(2):125–131. https://doi.org/10.1093/ijnp/pyz068Brett J, Daniels B, Karanges EA, Buckley NA, Schneider C, et al. Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study. // Br J Clin Pharmacol. – 2017. – V.83(11). – P.2581-2588. https://doi.org/10.1111/bcp.13369Brett J, Daniels B, Karanges EA, et al. Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study. Br J Clin Pharmacol. 2017;83(11):2581–2588. https://doi.org/10.1111/bcp.13369Arah OA, Westert GP, Hurst J, Klazinga NS. A conceptual framework for the OECD Health Care Quality Indicators Project. // Int J Qual Health Care. – 2006. – V.(1). – P. 5-13. https://doi.org/10.1093/intqhc/mzl024Arah OA, Westert GP, Hurst J, Klazinga NS. A conceptual framework for the OECD Health Care Quality Indicators Project. Int J Qual Health Care. 2006 (1):5-13. https://doi.org/10.1093/intqhc/mzl024Carinci F, Van Gool K, Mainz J, Veillard J, Pichora EC, et al. Towards actionable international comparisons of health system performance: expert revision of the OECD framework and quality indicators. // Int J Qual Health Care. – 2015. – V. 27(2). – P.137-46. https://doi.org/10.1093/intqhc/mzv004Carinci F, Van Gool K, Mainz J, et al. Towards actionable international comparisons of health system performance: expert revision of the OECD framework and quality indicators. Int J Qual Health Care. 2015. 27(2):137–146. https://doi.org/10.1093/intqhc/mzv004Yang SY, Chen LY, Najoan E, Kallivayalil RA, Viboonma K, et al. Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries: Fourth survey of Research on Asian Prescription Patterns on antipsychotics. // Psychiatry Clin Neurosci. – 2018. – V.72(8). – P.572-579. https://doi.org/10.1111/pcn.12676Yang SY, Chen LY, Najoan E, et al. Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries: Fourth survey of Research on Asian Prescription Patterns on antipsychotics. Psychiatry Clin Neurosci. 2018 Aug; 72(8):572-579. https://doi.org/10.1111/pcn.12676Toto S, Grohmann R, Bleich S, Frieling H, Maier HB, et al. Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP Study. // Int J Neuropsychopharmacol. – 2019. – V.22(9). – P.560-573. https://doi.org/10.1093/ijnp/pyz037Toto S, Grohmann R, Bleich S, et al. Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP Study. Int J Neuropsychopharmacol. 2019 Sep 1; 22(9):560-573. https://doi.org/10.1093/ijnp/pyz037Binder RL, Levy R. Extrapyramidal reactions in Asians. // Am J Psychiatry. - 1981. – V.138(9). – P.1243–1244. https://doi.org/10.1176/ajp.138.9.1243Binder RL, Levy R. Extrapyramidal reactions in Asians. Am J Psychiatry. 1981. 138(9):1243–1244. https://doi.org/10.1176/ajp.138.9.1243Ormerod S, McDowell SE, Coleman JJ, Ferner RE. Ethnic differences in the risks of adverse reactions to drugs used in the treatment of psychoses and depression: a systematic review and meta-analysis. // Drug Saf. - 2008. V.31(7). – P.597–607. https://doi.org/10.2165/00002018-200831070-00005Ormerod S, McDowell SE, Coleman JJ, Ferner RE. Ethnic differences in the risks of adverse reactions to drugs used in the treatment of psychoses and depression: a systematic review and meta-analysis. Drug Saf. 2008. 31(7):597–607. https://doi.org/10.2165/00002018-200831070-00005Lin SK. Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion? // Int J Neuropsychopharmacol. – 2020. – V.23(2). – P.125–131. https://doi.org/10.1093/ijnp/pyz068Lin SK. Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion?. Int J Neuropsychopharmacol. 2020;23(2):125–131. https://doi.org/10.1093/ijnp/pyz068Bjerre LM, Farrell B, Hogel M, Graham L, Lemay G, et al. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline. // Can Fam Physician. – 2018. – V.64(1). – P.17-27. PMID: 29358245.Bjerre LM, Farrell B, Hogel M, et al. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline. Can Fam Physician. 2018;64(1):17–27. PMID: 29358245Reeve E, Farrell B, Thompson W, Herrmann N, Sketris I, et al. Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. // Med J Aust. – 2019. – V.210(4). – P.174-179. https://doi.org/10.5694/mja2.50015Reeve E, Farrell B, Thompson W, et al. Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. Med J Aust. 2019;210(4):174‐179. https://doi.org/10.5694/mja2.50015Pottie K, Thompson W, Davies S, Grenier J, Sadowski CA, et al. Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline. // Can Fam Physician. – 2018. – V.64(5). – P.339-351. PMID: 29760253Pottie K, Thompson W, Davies S, et al. Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline. Can Fam Physician. 2018;64(5):339–351. PMID: 29760253Wallis KA, Andrews A, Henderson M. Swimming Against the Tide: Primary Care Physicians’ Views on Deprescribing in Everyday Practice. // Ann Fam Med. – 2017. – V.15(4). – P.341–346. https://doi.org/10.1370/afm.2094Wallis KA, Andrews A, Henderson M. Swimming Against the Tide: Primary Care Physicians' Views on Deprescribing in Everyday Practice. Ann Fam Med. 2017;15(4):341–346. https://doi.org/10.1370/afm.2094Kouladjian L, Gnjidic D, Reeve E, Chen TF, Hilmer SN. Health Care Practitioners’ Perspectives on Deprescribing Anticholinergic and Sedative Medications in Older Adults. // Ann Pharmacother. – 2016. – V.50(8). – P.625‐636. https://doi.org/10.1177/1060028016652997Kouladjian L, Gnjidic D, Reeve E, Chen TF, Hilmer SN. Health Care Practitioners' Perspectives on Deprescribing Anticholinergic and Sedative Medications in Older Adults. Ann Pharmacother. 2016;50(8):625‐636. https://doi.org/10.1177/1060028016652997Ailabouni NJ, Nishtala PS, Mangin D, Tordoff JM. Challenges and Enablers of Deprescribing: A General Practitioner Perspective. // PLoS One. – 2016. – V.11(4). - e0151066. https://doi.org/10.1371/journal.pone.0151066Ailabouni NJ, Nishtala PS, Mangin D, Tordoff JM. Challenges and Enablers of Deprescribing: A General Practitioner Perspective. PLoS One. 2016;11(4):e0151066. https://doi.org/10.1371/journal.pone.0151066Farrell B, Tsang C, Raman-Wilms L, Irving H, Conklin J, Pottie K. What are priorities for deprescribing for elderly patients? Capturing the voice of practitioners: a modified delphi process. // PLoS One. – 2015. – V.10(4). - e0122246. https://doi.org/10.1371/journal.pone.0122246Farrell B, Tsang C, Raman-Wilms L, Irving H, Conklin J, Pottie K. What are priorities for deprescribing for elderly patients? Capturing the voice of practitioners: a modified delphi process. PLoS One. 2015;10(4):e0122246. Published 2015 Apr 7. https://doi.org/10.1371/journal.pone.0122246Sheehan R, Hassiotis A, Walters K, Osborn D, Strydom A, Horsfall L. Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. // BMJ. – 2015. – V.351. - h4326. https://doi.org/10.1136/bmj.h4326Sheehan R, Hassiotis A, Walters K, Osborn D, Strydom A, Horsfall L. Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. BMJ. 2015;351:h4326. Published 2015 Sep 1. https://doi.org/10.1136/bmj.h4326Glover G.; Williams R.; et al. Prescribing of Psychotropic Drugs to People with Learning Disabilities and/or Autism by General Practitioners in England. - Public Health England: London, UK, 2015.Glover, G.; Williams, R.; et al. Prescribing of Psychotropic Drugs to People with Learning Disabilities and/or Autism by General Practitioners in England; Public Health England: London, UK, 2015. 67 p.Flood B. De-Prescribing of Psychotropic Medications in the Adult Population with Intellectual Disabilities: A Commentary. // Pharmacy (Basel). – 2018. – V.6(2). – P.28. https://doi.org/10.3390/pharmacy6020028.Flood B. De-Prescribing of Psychotropic Medications in the Adult Population with Intellectual Disabilities: A Commentary. Pharmacy (Basel). 2018;6(2):28. Published 2018 Mar 30. https://doi.org/10.3390/pharmacy6020028.British Pharmacological Society. Ten Principles of Good Prescribing. British Pharmacological Society: London, UK, 2012.British Pharmacological Society. Ten Principles of Good Prescribing; British Pharmacological Society: London, UK, 2012.

The authors declare that there are no conflicts of interest present.